MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7500
+0.0200
+2.74%
After Hours: 0.7500 0 0.00% 18:33 05/29 EDT
OPEN
0.7313
PREV CLOSE
0.7300
HIGH
0.7751
LOW
0.6800
VOLUME
436.34K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.4300
MARKET CAP
20.71M
P/E (TTM)
-0.7210
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RGLS stock price target is 1.000 with a high estimate of 1.500 and a low estimate of 0.5000.

EPS

RGLS News

More
Penny Stocks to Buy Using Technical Analysis for June 2020
These low-priced stocks may prove exempt from a potential downtrend based on their bullish technical signals.
Investopedia · 2d ago
Regulus Therapeutics EPS misses by $0.13
Regulus Therapeutics (NASDAQ:RGLS): Q1 GAAP EPS of -$0.25 misses by $0.13. Revenue under strategic alliances of $0.01M. Cash and cash equivalents of $28.1M
seekingalpha · 05/15 01:24
Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2020
PR Newswire · 05/14 20:07
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?
Regulus (RGLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 05/07 16:30
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Lowers Price Target to $1.5
HC Wainwright & Co. reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and lowers the price target from $2 to $1.5.
Benzinga · 05/04 11:21
Regulus Therapeutics EPS beats by $0.01, beats on revenue
seekingalpha · 03/13 01:49
Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
PR Newswire · 03/12 21:37
Regulus Therapeutics Q4 EPS $(0.23) Up From $(0.98) YoY
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.23) per share. This is a 76.53 percent increase over losses of $(0.98) per share from the same period last year.
Benzinga · 03/12 20:37

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About RGLS

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
More

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.